
AS THE summit between the African Union and European Union (EU-AU summit) came to a close on February 18, the EU’s dedication to ensuring equitable access to Covid-19 products remained murky.
While Ursula von der Leyen, president of the European Commission, stated that the two unions had had a very constructive discussion on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver, the meeting resulted in little more than a tepid statement and a new deadline for reaching an agreement on intellectual property rights during the pandemic. Von der Leyen also stated: “We share the same goal. We have different ways to reach that goal.”
In reality, it would seem the AU and the EU have very different goals. While delegates from different African countries made a point of supporting a suspension of intellectual property rights on key Covid-19 products, EU politicians continue to focus their energies on postponing the TRIPS waiver as much as possible and protecting the profits of pharmaceutical companies based in the global North.



